Feasibilty and Acceptability of Amani

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT07648043
Phase
EARLY_PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Amani — BEHAVIORAL
    Amani is a multi-component VR supportive care intervention specifically tailored for adults with SCD. Amani integrates mindfulness-based pain management exercises, psychoeducational modules to build adaptive coping strategies, and facilitated VR group sessions to reduce isolation and foster peer support.

Study Details

Adults with sickle cell disease (SCD) experience severe pain, emotional distress, and social isolation that diminish their quality of life. This project will test Amani, a novel virtual reality supportive care intervention designed to improve coping skills and strengthen peer support. If feasible and acceptable, Amani offers an accessible digital supportive care intervention to improve psychological well-being and quality of life among individuals living with SCD and potentially other chronic illnesses.

Key Dates

Start date
Jan 1, 2027
Status verified
May 2026
Primary completion
Feb 28, 2028
Completion
Apr 30, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE

Arms

  • Experimental: Amani
    Patients enrolled will receive Amani, which is a virtual reality intervention administered over 5 weeks. Amani is a virtual reality based supportive care intervention specifically tailored for adults with SCD. Amani integrates mindfulness-based pain management exercises, psychoeducational modules to build adaptive coping strategies, and facilitated group sessions in virtual reality to reduce isolation and foster peer support

Primary Outcome Measure

Feasibility [ Time Frame: From enrollment to end of treatment (6 weeks) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts01867
Richard Newcomb, MD
[email protected]
617-726-2000
[email protected]
Richard A Newcomb, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By condition
Sickle cell disease
By research site
Massachusetts General Hospital· Boston, MA

Related Studies